Research programme: anti-microbial therapeutics - Assembly Biosciences

Drug Profile

Research programme: anti-microbial therapeutics - Assembly Biosciences

Alternative Names: AB M102; AB M103; ABI M201; ABI M301; ABI-M101; ABM-101; Gemicel based therapeutics - Ventrus Biosciences; Gemicel based therapeutics -Assembly Biosciences; Microbiome therapeutics - Assembly Biosciences

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Assembly Biosciences
  • Class Bacteria; Proteins; Small molecules; Viruses
  • Mechanism of Action Bacterial toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium infections
  • Research Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 09 Jan 2017 Early research in Crohn's disease in USA (unspecified route)
  • 09 Jan 2017 Early research in Inflammatory bowel disease in USA (unspecified route)
  • 09 Jan 2017 Early research in Ulcerative colitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top